US Stock IR Daily – April 17, 2026 (1 reports)

• Abbott Laboratories filed a Form 8-K on April 17, 2026, reporting an “Other Event.”
• On April 10, 2026, the United States District Court for the Northern District of Illinois signed an “Order Preliminarily Approving Proposed Settlement, Directing The Issuance Of Notice, And Setting A Final Settlement Hearing.”
• This order pertains to six consolidated shareholder derivative lawsuits, previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024, and December 31, 2025.
• The lawsuits, titled “In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation,” were filed against certain current and former directors and officers of the company.
• A copy of the “Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear” is filed as Exhibit 99.1 to the Form 8-K.

This announcement indicates a significant procedural advancement in the resolution of shareholder derivative lawsuits involving Abbott Laboratories. The preliminary approval of the proposed settlement suggests that the litigation is progressing towards a definitive resolution, with the upcoming final settlement hearing being a key next step in this process.